Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gynaecological cancers

4654 - Long term quality of life among epithelial ovarian cancer patients: The GINECO case/control VIVROVAIRE Study

Date

09 Sep 2017

Session

Gynaecological cancers

Presenters

Florence Joly Lobbedez

Citation

Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372

Authors

F. Joly Lobbedez1, A. Floquet2, E. Kalbacher3, N. Heutte4, D. Berton-Rigaud5, O. Tredan6, M. Fabbro7, A.M. Savoye8, J.E. Kurtz9, J. Alexandre10, P. Follana11, V. Delecroix12, N. Dohollou13, C. Roemer-Becuwe14, A. Lesoin15, A. Lortholary16, G. De Rauglaudre17, J. Grellard18, D. Ahmed-Lecheheb19, C. Lhomme20

Author affiliations

  • 1 Medical Oncology &clinical Research&inserm U1086"anticipe" (interdisciplinary Research Unit For Cancers Prevention And Treatment, Axis Bioticla "biology And Innovative Therapeutics For Ovarian Cancers", UNICANCER, Centre François Baclesse&Normandie Univ, UNICAEN, 14076 - CAEN/FR
  • 2 Medical Oncology, UNICANCER,Institute Bergonié, 33076 - Bordeaux/FR
  • 3 Medical Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 4 Clinical Research Department&cetaps-ufr Staps, UNICANCER, Centre François Baclesse&CETAPS-STAPS Univ, Rouen, 14076 - CAEN/FR
  • 5 Medical Oncology, UNICANCER, ICO Centre René Gauducheau, 44805 - Saint-Herblain/FR
  • 6 Medical Oncology, UNICANCER, Centre Léon Bérard, 69008 - Lyon/FR
  • 7 Medical Oncology, UNICANCER, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 8 Medical Oncology, UNICANCER, Institut Jean Godinot, 51056 - Reims/FR
  • 9 Oncology, CHU Hautepierre, 67200 - Strasbourg/FR
  • 10 Oncology Department, Certim, Hôpital Cochin, 75679 - Paris/FR
  • 11 Medical Oncology, UNICANCER, Centre Antoine Lacassagne, 6100 - Nice/FR
  • 12 Medical Oncology, Clinique Mutualiste de l'Estuaire, 44606 - Saint-Nazaire/FR
  • 13 Oncology-radiotherapy, Polyclinique Bordeaux Nord Aquitaine, 33077 - Bordeaux/FR
  • 14 Oncology, Centre d'Oncologie de Gentilly, 54100 - NANCY/FR
  • 15 Medical Oncology, UNICANCER, Centre Oscar Lambret, 59020 - Lille/FR
  • 16 Medical Oncology, Centre Catherine de Sienne, 44202 - Nantes/FR
  • 17 Medical Oncology, Institut Sainte Catherine, 84918 - Avignon/FR
  • 18 Clinical Research Department, UNICANCER, Centre François Baclesse, 14076 - CAEN/FR
  • 19 Clinical Research Department&inserm U1086, UNICANCER, Centre François Baclesse&INSERM U1086, 14076 - CAEN/FR
  • 20 Medical Oncology, UNICANCER, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
More

Resources

Abstract 4654

Background

If epithelial ovarian cancer (EOC) had a poor prognosis, more than 20% of patients (pts) can expected long remission. Few data are available on long term quality of life (QoL) in these pts and results reported were usually not compared to those of healthy controls. VIVROVAIRE was a large national case-control study comparing pts reported outcomes (PROs) among EOC pts without relapse within 3 years after first line treatment and a group of healthy women.

Methods

Pts were recruited in 27 French centers and clinical characteristics were issued from medical charts. Controls were randomized from electoral lists. Pts and controls matched on age. They filled in a form including PROs questionnaires: QoL, neurotoxicity and fatigue (FACT/G, FACT/O, FACT/GOG-Ntx, FACT/F), anxiety and depression (HADS), sleep disturbance (ISI) and Physical activity (IPAQ).

Results

318 pairs were analysed (from 349 pts and 327 controls included). Median age: 65 (20-86), high level of education: 52% and 58%, respectively. Pts characteristics: FIGO stage I/II (49%), III/IV (47%) unknown (4%); major histology, serous (50%), endometrioid (16%), clear cells (8%), mucinous (4%). BRCA1/2 mutations (n = 21; 15%), unknown (n = 168). 99% of the pts had a surgery and 96% received platinum based chemotherapy, associated with antiangiogenic agent (14%) Interval from first line therapy: median 5 years [2 to 24]. Pts reported lower physical and functioning QoL scores (p = 0.03 and p = 0.0002), higher score of fatigue (p 

Conclusions

Compared to healthy women, EOC pts presented poorer long term QoL, fatigue with important neurotoxicity and digestive symptoms. Physicians have to take in count of the late effects of treatments to help the pts to cope with the sequelae.

Clinical trial identification

Not applicable (Observational study)

Study approved by CCTIRS and CNIL

Legal entity responsible for the study

Centre François Baclesse

Funding

Fondation de France; Ligue Nationale Contre le Cancer

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.